Skip to main content
Top
Published in: PharmacoEconomics 8/2013

01-08-2013 | Review Article

Overview of Parametric Survival Analysis for Health-Economic Applications

Authors: K. Jack Ishak, Noemi Kreif, Agnes Benedict, Noemi Muszbek

Published in: PharmacoEconomics | Issue 8/2013

Login to get access

Abstract

Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric survival analysis methods can be applied to identify an appropriate statistical model for the observed data, which can then be extrapolated to derive a complete time-to-event curve. This paper describes the properties of the most commonly used statistical distributions as a basis for these models and describes an objective process of identifying the most suitable parametric distribution in a given dataset. The approach can be applied with both individual-patient data as well as with survival probabilities derived from published Kaplan–Meier curves. Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial.
Footnotes
1
This topic is also covered in a report titled “Extrapolating clinical time-to-event outcomes” for the MRC Methodology Project on Extrapolation of RCT Evidence involving Sheffield University.
 
Literature
1.
go back to reference Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141. Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141.
2.
go back to reference Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867–75.CrossRefPubMed Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867–75.CrossRefPubMed
3.
go back to reference Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMed Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMed
4.
go back to reference Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://www.nicedsu.org.uk. Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://​www.​nicedsu.​org.​uk.
5.
go back to reference Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003. Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003.
6.
go back to reference Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed
7.
go back to reference Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005.
8.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef
9.
go back to reference Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75–83. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75–83.
10.
go back to reference Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187–220. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187–220.
11.
go back to reference Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRefPubMed Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRefPubMed
12.
go back to reference Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed
13.
go back to reference StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011. StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011.
14.
15.
go back to reference Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–35.CrossRefPubMed Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–35.CrossRefPubMed
16.
go back to reference Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528–38.CrossRefPubMed Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528–38.CrossRefPubMed
17.
go back to reference Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942–951. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942–951.
18.
go back to reference Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–97.CrossRefPubMed Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–97.CrossRefPubMed
19.
go back to reference Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.
20.
go back to reference Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34.
21.
go back to reference Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383–404.CrossRefPubMed Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383–404.CrossRefPubMed
22.
go back to reference Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53.CrossRefPubMed Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53.CrossRefPubMed
23.
go back to reference Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMed Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMed
24.
go back to reference Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557–71.CrossRefPubMed Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557–71.CrossRefPubMed
25.
go back to reference Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559–66.CrossRefPubMed Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559–66.CrossRefPubMed
26.
go back to reference Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.CrossRefPubMed Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.CrossRefPubMed
27.
go back to reference Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii–ix, xi–162. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii–ix, xi–162.
28.
go back to reference Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1–184, iii–iv. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1–184, iii–iv.
29.
go back to reference Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221.
Metadata
Title
Overview of Parametric Survival Analysis for Health-Economic Applications
Authors
K. Jack Ishak
Noemi Kreif
Agnes Benedict
Noemi Muszbek
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2013
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0064-3

Other articles of this Issue 8/2013

PharmacoEconomics 8/2013 Go to the issue

Original Research Article

A Choice That Matters?